keyword
MENU ▼
Read by QxMD icon Read
search

oral antineoplastic

keyword
https://www.readbyqxmd.com/read/29016351/ameliorative-effect-of-gallic-acid-on-doxorubicin-induced-cardiac-dysfunction-in-rats
#1
Temiday O Omóbòwálé, Ademola A Oyagbemi, Ayorinde M Folasire, Temitayo O Ajibade, Ebunoluwa R Asenuga, Olumuyiwa A Adejumobi, Olufunke E Ola-Davies, Orotusin Oyetola, Gana James, Adeolu A Adedapo, Momoh A Yakubu
BACKGROUND: The use of doxorubicin (DOX) as an antineoplastic agent has been greatly limited because of the myriad of toxic sequelae associated with it. The aim of this study was to assess the protective effects of gallic acid (GA) on DOX-induced cardiac toxicity in rats. METHODS: Sixty male rats (Wistar strain) were used in this study. They were divided into six groups (A-F) each containing 10 animals. Group A was the control. Rats in Groups B, C, and D were treated with DOX at the dosage of 15 mg/kg body weight i...
October 9, 2017: Journal of Basic and Clinical Physiology and Pharmacology
https://www.readbyqxmd.com/read/28987366/the-impact-of-gallic-acid-on-the-methotrexate-induced-kidney-damage-in-rats
#2
Halil Asci, Ozlem Ozmen, Hamit Yasar Ellidag, Bunyamin Aydin, Ercan Bas, Necat Yilmaz
Prolonged use of an antineoplastic agent methotrexate (MTX), can cause numerous side effects such as nephrotoxicity. The aim of this study was to examine the effects of MTX on kidneys and demonstrate the protective effects of gallic acid (GA). Twenty-four, male, rats distributed into three groups. Each groups consisted eight rats and only saline was administered to the control group. The MTX group received a single dose (20 mg/kg) MTX intraperitoneally. The MTX + GA group received same dose MTX and 100 mg/kg GA orally during the 7 days...
October 2017: Journal of Food and Drug Analysis
https://www.readbyqxmd.com/read/28969534/perioperative-management-of-female-hormone-medications
#3
Lynsey A Seim, Joan M Irizarry-Alvarado
BACKGROUND: No clear guideline exists for the management of female hormone therapy in the perioperative period. Besides oral contraceptives (OCPs), hormone medications have been prescribed to treat cancer, osteoporosis, and menopausal symptoms. Since the introduction of OCPs in the 1960s, the thromboembolic risk associated with these medications has been studied and alterations have been made in the hormone content. The continuation of hormone therapy in the perioperative period and its possible interactions with commonly used anesthetic agents are important information for all perioperative health care providers...
September 26, 2017: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/28921641/pharmacokinetic-guided-dosing-of-new-oral-cancer-agents
#4
Catherine J Lucas, Jennifer H Martin
Generally, licensed drug-dosing recommendations for chemotherapy are based on results from clinical trials in which subjects are usually of relatively normal body size, middle-aged, and are relatively racially homogeneous, with minimal comorbidity and specific tumor characteristics. Very few nontrial patients meet these characteristics, resulting in clinical practice having to extrapolate dosing recommendations to the specific patient. There is insufficient research on the impact of obesity-associated physiological changes prevalent in patients with common cancers on standard pharmacokinetic and pharmacodynamic parameters...
October 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28912872/preclinical-trial-of-the-multi-targeted-lenvatinib-in-combination-with-cellular-immunotherapy-for-treatment-of-renal-cell-carcinoma
#5
Chengkuan Cai, Jingyuan Tang, Baixin Shen, Liucheng Ding, Yunpeng Shao, Zhengsen Chen, Yinchao Ma, Haoliang Xue, Zhongqing Wei
Lenvatinib is an oral, multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor β, RET and KIT. Cellular immunotherapy has the potential to be a highly targeted treatment, with low toxicity to normal tissues and a high capacity to eradicate tumor tissue. The present study assessed the safety, maximum tolerated dose (MTD) and preliminary antitumor activity of lenvatinib and cellular immunotherapy in a murine model of renal cell carcinoma (RCC)...
October 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28911059/forcing-the-vicious-circle-sarcopenia-increases-toxicity-decreases-response-to-chemotherapy-and-worsens-with-chemotherapy
#6
F Bozzetti
Sarcopenia has recently emerged as a new condition that, independently from malnutrition, may adversely affect the prognosis of cancer patients. Purpose of this narrative review is to define the prevalence of sarcopenia in different primaries, its role in leading to chemotherapy toxicity and decreased compliance with the oncological therapy and the effect of some drugs on the onset of sarcopenia. Finally, the review aims to describe the current approaches to restore the muscle mass through nutrition, exercise and anti-inflammatory agents or multimodal programmes with a special emphasis on the results of randomized controlled trials...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28867970/occurrence-and-recurrence-of-hepatocellular-carcinoma-after-successful-direct-acting-antiviral-therapy-for-patients-with-chronic-hepatitis-c-virus-infection
#7
Sirisha Grandhe, Catherine T Frenette
Chronic hepatitis C virus (HCV) infection has generally been associated with a slightly increased risk of developing hepatocellular carcinoma (HCC). For the past several decades, most patients with chronic HCV cirrhosis have been treated with pegylated interferon and ribavirin therapies, which were known to achieve sustained virologic response (SVR) but also carried their own side effects and toxicities. The recent implementation of direct-acting antiviral (DAA) treatments revealed an increased efficacy in difficult-to-treat populations and higher adherence rates given the all-oral nature of the regimens...
July 2017: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28756607/a-randomized-open-label-two-way-crossover-single-dose-bioequivalence-study-of-temozolomide-200%C3%A2-mg-m-2-dralitem-%C3%A2-vs-temodal-%C3%A2-capsules-in-patients-with-primary-tumors-of-the-central-nervous-system-under-fasting-conditions
#8
Alejandro Muggeri, Miguel Vago, Sebastián Pérez, Marcelo Rubio, Cecilia González, Cristian Magariños, Mónica Rosenberg, Fernando Costa, Santiago Pérez-Lloret
BACKGROUND: Temozolomide is an antineoplastic agent of proven efficacy against high-grade gliomas. PURPOSE: The objective of this crossover, single-dose, bioequivalence study was to compare the rate and extent of absorption of oral temozolomide after administration of the study product (Dralitem(®), Monte Verde Sociedad Anónima) and the reference product (Temodal(®), originator product manufactured by Schering Plough Laboratories) in patients with primary central nervous system (CNS) tumors under fasting conditions...
July 29, 2017: Drugs in R&D
https://www.readbyqxmd.com/read/28698536/metformin-use-associated-with-lower-risk-of-cancer-in-patients-with-diabetes-mellitus-type-2
#9
Jasna Kusturica, Aida Kulo Ćesić, Edis Gušić, Sanita Maleškić, Maida Rakanović-Todić, Damir Šečić
Aim In order to increase the database related to the antineoplastic potential of metformin, association between the use of metformin and risk of cancer occurence in patients with diabetes mellitus type 2 (DM2) was investigated. Methods In this cross-sectional study, medical records of patients with DM2 were reviewed for cancer occurence. Data on age, body mass index (BMI), alcohol and nicotine consumption, glucose and HbA1c levels, duration of DM2, medication used in the treatment of DM2 and cancer occurence were collected and analyzed...
August 1, 2017: Medicinski Glasnik
https://www.readbyqxmd.com/read/28698442/incidence-of-ophthalmic-disorders-in-patients-treated-with-the-antineoplastic-agent-s-1
#10
Kanae Moriya, Hisanori Shimizu, Satoko Handa, Tadanori Sasaki, Yasutsuna Sasaki, Haruo Takahashi, Seigo Nakamura, Hitoshi Yoshida, Yasuhisa Kato
S-1 is an oral antineoplastic agent containing tegafur, gimeracil, and oteracil potassium. Recently, ophthalmic disorders, particularly epiphora, have been reported. We retrospectively investigated the incidence of ophthalmic disorders in patients treated with a regimen containing S-1 at our institution. Ophthalmic disorders were noted in 28 of 261 patients(10.7%). These included epiphora(17 cases), eye discharge(10 cases), conjunctivitis(6cases ), blurred vision(3 cases), and eye discomfort(2 cases), as well as eye pain, pruritus, dry eye, hordeolum, and visual loss(1 case each)...
June 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28667459/clinical-pharmacokinetics-and-pharmacodynamics-of-panobinostat
#11
REVIEW
Mathilde Van Veggel, Elsbeth Westerman, Paul Hamberg
Histone deacetylase (HDAC) inhibitors cause an increase in acetylation that leads to an increase in DNA transcription and accumulation of different proteins, reducing cell proliferation and inducing cell death. Panobinostat is a first-in-line HDAC inhibitor approved for treating multiple myeloma in combination with bortezomib and dexamethasone. It is a pan-deacetylase inhibitor and therefore inhibits not only HDAC but also other deacetylases. The main mechanism of action of panobinostat is to inhibit HDAC, which causes cell cycle arrest and apoptosis, leading to it being an antineoplastic drug...
June 30, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28629835/ruthenium-complex-exerts-antineoplastic-effects-that-are-mediated-by-oxidative-stress-without-inducing-toxicity-in-walker-256-tumor-bearing-rats
#12
Carlos Eduardo Alves de Souza, Helen de Morais Alves de Souza, Maria Carolina Stipp, Claudia Rita Corso, Claudia Martins Galindo, Carolina Riverin Cardoso, Rosangela Locatelli Dittrich, Edneia Amancio de Souza Ramos, Giseli Klassen, Rose Maria Carlos, Sílvia Maria Suter Correia Cadena, Alexandra Acco
The present study evaluated the in vivo antitumor effects and toxicity of a new Ru(II) compound, cis-(Ru[phen]2[ImH]2)(2+) (also called RuphenImH [RuC]), against Walker-256 carcinosarcoma in rats. After subcutaneous inoculation of Walker-256 cells in the right pelvic limb, male Wistar rats received 5 or 10mgkg(-1) RuC orally or intraperitoneally (i.p.) every 3 days for 13 days. A positive control group (2mgkg(-1) cisplatin) and negative control group (vehicle) were also used. Tumor progression was checked daily...
June 17, 2017: Free Radical Biology & Medicine
https://www.readbyqxmd.com/read/28612006/cisplatin-therapy-does-not-worsen-renal-function-in-severe-antenatal-bartter-syndrome
#13
Thomas R Welch, David R Shaffer, Darren R Feldman
A 30-year-old man with severe antenatal Bartter syndrome, diagnosed and treated in infancy, developed testicular carcinoma. Despite the known renal complications of cisplatin, this drug was used for his chemotherapy because of its superior antineoplastic effect. Nonsteroidal anti-inflammatory drug administration was continued during cisplatin therapy. Despite an increase in his oral potassium requirement, renal function was maintained following completion of chemotherapy. In spite of its significant associated nephrotoxicity, cisplatin can be used in patients with severe antenatal Bartter syndrome if required for therapy of malignancy...
May 2017: Case Reports in Nephrology and Dialysis
https://www.readbyqxmd.com/read/28608993/oral-fluoropyrimidine-versus-intravenous-5-fluorouracil-for-the-treatment-of-advanced-gastric-and-colorectal-cancer-meta-analysis
#14
Linlin Zhang, Xiaoli Xing, Fanlu Meng, Yan Wang, Diansheng Zhong
BACKGROUND: 5-Fluorouracil(5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers. Continuous infusion would be the optimal way of its administration, however, may usually cause thrombosis, infection and prolonged hospital stay. Oral fluoropyrimidines would be an attractive alternative, but their efficiency and toxicities for the treatment of gastric and colorectal cancer are still obscure as compared with infusion 5-Fu. METHODS: Literature retrieval, trials selection and assessment, data collection and statistic analysis were performed according to the Cochrane Handbook...
June 13, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28595616/phase-i-study-of-oral-ridaforolimus-in-combination-with-paclitaxel-and-carboplatin-in-patients-with-solid-tumor-cancers
#15
Hye Sook Chon, Sokbom Kang, Jae K Lee, Sachin M Apte, Mian M Shahzad, Irene Williams-Elson, Robert M Wenham
BACKGROUND: Ridaforolimus is a mammalian target of rapamycin inhibitor that has activity in solid tumors. Paclitaxel and carboplatin have broad antineoplastic activity in many cancers. This phase I trial was conducted to determine the safety profile, maximal tolerated dose, and recommended phase II dose and schedule of oral ridaforolimus combined with paclitaxel and carboplatin in patients with solid tumor cancers. METHODS: Eligible patients with advanced solid tumor cancers received oral 10 to 30 mg ridaforolimus daily for 5 consecutive days per week combined with intravenous paclitaxel (175 mg/m(2)) and carboplatin (area under the curve [AUC] 5-6 mg/mL/min) in 3-week cycles...
June 8, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28509613/impact-of-a-specialty-pharmacy-case-management-service-on-adherence-in-patients-receiving-oral-antineoplastic-agents
#16
Grant Middendorff, Rachel Elsey, Brian Lounsbery, Roxanne Chadwell
Background Patients receiving treatment with oral antineoplastic agents encounter several barriers to adherence, which may include high medication costs, limited access to specialty medications, severe adverse effects, complex medication regimens, and special handling precautions. Medication nonadherence not only reduces the efficacy of drug therapy but also has the potential to increase healthcare expenditures due to disease-related hospitalizations. Although several previous studies have examined patient adherence to oral antineoplastic agents, few have examined the impact of a specialty pharmacy case management service...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28452475/hydrolysis-in-acidic-environment-and-degradation-of-satraplatin-a-joint-experimental-and-theoretical-investigation
#17
Ida Ritacco, Merriam Al Assy, Mohamed K Abd El-Rahman, Sherif Ashraf Fahmy, Nino Russo, Tamer Shoeib, Emilia Sicilia
For the synthesis and selection of active platinum-based anticancer drugs that perform better than cisplatin and its analogues, six-coordinate octahedral Pt(IV) complexes appear to be promising candidates as, being kinetically more inert and more resistant to ligand substitution than four-coordinate Pt(II) centers, they are able to minimize unwanted side reactions with biomolecules prior to DNA binding. Due to their kinetic inertness, Pt(IV) complexes have also been exploited to bypass inconvenient intravenous administration...
May 15, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28429653/clinical-development-of-fenretinide-as-an-antineoplastic-drug-pharmacology-perspectives
#18
REVIEW
Jason P Cooper, C Patrick Reynolds, Hwangeui Cho, Min H Kang
Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells. Despite substantial in vitro cytotoxicity, response rates in early clinical trials with 4-HPR have been less than anticipated, likely due to the low bioavailability of the initial oral capsule formulation. Several clinical studies have shown that the oral capsule formulation at maximum tolerated dose (MTD) achieved <10 µmol/L concentrations in patients. To improve bioavailability of 4-HPR, new oral powder (LYM-X-SORB®, LXS) and intravenous lipid emulsion (ILE) formulations are being tested in early-phase clinical trials...
June 2017: Experimental Biology and Medicine
https://www.readbyqxmd.com/read/28418845/preclinical-development-of-g1t38-a-novel-potent-and-selective-inhibitor-of-cyclin-dependent-kinases-4-6-for-use-as-an-oral-antineoplastic-in-patients-with-cdk4-6-sensitive-tumors
#19
John E Bisi, Jessica A Sorrentino, Jamie L Jordan, David D Darr, Patrick J Roberts, Francis X Tavares, Jay C Strum
Inhibition of the p16INK4a/cyclin D/CDK4/6/RB pathway is an effective therapeutic strategy for the treatment of estrogen receptor positive (ER+) breast cancer. Although efficacious, current treatment regimens require a dosing holiday due to severe neutropenia potentially leading to an increased risk of infections, as well as tumor regrowth and emergence of drug resistance. Therefore, a next generation CDK4/6 inhibitor that can inhibit proliferation of CDK4/6-dependent tumors while minimizing neutropenia could reduce both the need for treatment holidays and the risk of inducing drug resistance...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28349509/a-new-emerging-oral-infection-raoultella-planticola-in-a-boy-with-haematological-malignancy
#20
E Bardellini, F Amadori, R F Schumacher, I Foresti, A Majorana
BACKGROUND: Oral mucositis is a common complication in pediatric cancer patients, affecting up to 80% of children. Due to neutropenia and disruption of the mucosal barrier, chemotherapy-induced oral mucositis is often complicated by super-infections. CASE REPORT: A 16-years old male with stage 3 Burkitt's lymphoma developed chemotherapy induced oral mucositis grade 3 (according to WHO scale). Ulcers were quickly growing (reaching a maximum diameter of 3 cm) and became greyish in colour, resulting in dysphagia and pain...
March 27, 2017: European Archives of Paediatric Dentistry: Official Journal of the European Academy of Paediatric Dentistry
keyword
keyword
86616
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"